RPA-LF Assay Evaluated for Cutaneous Leishmaniasis in Colombia
|
By LabMedica International staff writers Posted on 17 May 2021 |

Image: Results of the Recombinase Polymerase Amplification-Lateral Flow (RPA-LF) assay for cutaneous leishmaniasis (Photo courtesy of University of Texas Medical Branch)
Cutaneous leishmaniasis (CL) is a recognized public health challenge in the Americas, with an average of 55,000 cases per year between 2001 and 2018 in 17 countries of the region. Most cases (79.4%) have been acquired in and continue to occur in rural areas.
Currently available diagnostic methods for CL have several limitations. Light microscopic analysis of smears obtained from cutaneous lesions is the most commonly used diagnostic method for CL because of its low cost, yet its sensitivity varies widely depending on the experience and skill of the operator. In addition, sensitivity of microscopy is diminished in lesions of longer duration in chronic lesions with their notorious low parasite burden.
A team of tropical medicine specialists from the University of Texas Medical Branch (Galveston, TX, USA) and the Universidad Icesi (Cali, Colombia) conducted a cross-sectional study of diagnostic test performance between January 2018 and July 2019. There were 118 participants ≥2 years of age, with ulcerated skin lesions of more than two weeks’ duration were eligible and enrolled consecutively either in their residence (in rural Tumaco) by community health workers, or when seeking care at the primary health facility in urban Tumaco or the reference center laboratory in Cali.
The team utilized a composite “gold standard” based on microscopy of lesion smear, culture, histopathology of biopsy and qPCR18S as a reference. Minimally invasive swab and FTA filter paper samples were obtained by community health workers and highly trained technicians from ulcerated lesions. The investigators evaluated the diagnostic test performance of Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA, coupled with a lateral flow (LF) immunochromatographic strip, in a field setting and a laboratory reference center.
The scientists reported that the sensitivity and specificity of RPA-LF in the reference lab scenario were 87% (95%CI 74–94) and 86% (95%CI 74–97), respectively. In the field scenario, the sensitivity was 75% (95%CI 65–84) and specificity 89% (95%CI 78–99). Positive likelihood ratios in both scenarios were higher than six while negative likelihood ratios ranged to 0.2–0.3 supporting the usefulness of RPA-LF to rule-in and potentially to rule-out infection.
The authors concluded that RPA-LF is a valid, efficacious test to diagnose CL that could replace or complement microscopy in rural areas. Its combination with non-invasive sampling and low complexity requirements for processing and interpreting results position this test as an achievable alternative for diagnosis of CL at points of care in Colombia. The study was published on April 28, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Texas Medical Branch
Universidad Icesi
Currently available diagnostic methods for CL have several limitations. Light microscopic analysis of smears obtained from cutaneous lesions is the most commonly used diagnostic method for CL because of its low cost, yet its sensitivity varies widely depending on the experience and skill of the operator. In addition, sensitivity of microscopy is diminished in lesions of longer duration in chronic lesions with their notorious low parasite burden.
A team of tropical medicine specialists from the University of Texas Medical Branch (Galveston, TX, USA) and the Universidad Icesi (Cali, Colombia) conducted a cross-sectional study of diagnostic test performance between January 2018 and July 2019. There were 118 participants ≥2 years of age, with ulcerated skin lesions of more than two weeks’ duration were eligible and enrolled consecutively either in their residence (in rural Tumaco) by community health workers, or when seeking care at the primary health facility in urban Tumaco or the reference center laboratory in Cali.
The team utilized a composite “gold standard” based on microscopy of lesion smear, culture, histopathology of biopsy and qPCR18S as a reference. Minimally invasive swab and FTA filter paper samples were obtained by community health workers and highly trained technicians from ulcerated lesions. The investigators evaluated the diagnostic test performance of Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA, coupled with a lateral flow (LF) immunochromatographic strip, in a field setting and a laboratory reference center.
The scientists reported that the sensitivity and specificity of RPA-LF in the reference lab scenario were 87% (95%CI 74–94) and 86% (95%CI 74–97), respectively. In the field scenario, the sensitivity was 75% (95%CI 65–84) and specificity 89% (95%CI 78–99). Positive likelihood ratios in both scenarios were higher than six while negative likelihood ratios ranged to 0.2–0.3 supporting the usefulness of RPA-LF to rule-in and potentially to rule-out infection.
The authors concluded that RPA-LF is a valid, efficacious test to diagnose CL that could replace or complement microscopy in rural areas. Its combination with non-invasive sampling and low complexity requirements for processing and interpreting results position this test as an achievable alternative for diagnosis of CL at points of care in Colombia. The study was published on April 28, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Texas Medical Branch
Universidad Icesi
Latest Microbiology News
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Channels
Clinical Chemistry
view channel
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read moreMolecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







